Clinical Trial

A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2027-11 2026-07-23
minor Completion pushed: 2026-07 -> 2027-11 2026-07-23
Trial Details
NCT Number NCT07347249
Lead Sponsor Hemab ApS
Conditions Congenital Factor VII Deficiency
Enrollment 18 participants
Start Date 2026-03-11
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-22